Addressing Physician Barriers to Administering Cyclin-dependent Kinases 4 and 6 Inhibitors in First-line Treatment of Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast cancer

TY - JOUR

T1 - Addressing Physician Barriers to Administering Cyclin-dependent Kinases 4 and 6 Inhibitors in First-line Treatment of Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast cancer

AU - Mahtani, Reshma

AU - Vogel, Charles L.

N1 - Combination therapy with a cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor and an aromatase inhibitor (AI) for first-line treatment of postmenopausal women with advanced breast cancer (ABC) has demonstrated improvement in progression-free survival (PFS) over AI monotherapy without adding substan ...

PY - 2019

Y1 - 2019

UR - https://pubmed.ncbi.nlm.nih.gov/30655702/

M3 - Article

VL - 11

JO - Cancer management and research

JF - Cancer management and research

ER -